Evaluation of Pharmacokinetic and Pharmacodynamic Parameters of Somatropin Produced by Laboratory Blausiegel Indústria e Comércio Ltda., Compared to Saizen® From Laboratory Merck Serono S.A.
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01494779 |
Recruitment Status
: Unknown
Verified September 2012 by Azidus Brasil.
Recruitment status was: Not yet recruiting
First Posted
: December 19, 2011
Last Update Posted
: September 25, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
GH Deficiency (GHD) Growth Retardation | Drug: Somatropin | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 32 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Study Start Date : | March 2013 |
Estimated Primary Completion Date : | June 2013 |
Estimated Study Completion Date : | August 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: Somatropin Test
Somatropin of Blausiegel Indústria e Comércio Ltda.
|
Drug: Somatropin
single subcutaneous dose of 5mg
|
Active Comparator: Saizen
Somatropin of Merck Serono
|
Drug: Somatropin
single subcutaneous dose of 5mg
|
- The primary efficacy endpoint will be based in the investigation of pharmacokinetics and pharmacodynamics of somatropin in research subjects after administration of single dose, sc, of the drug. [ Time Frame: PK: 0, 1, 2, 3, 3:30, 4, 4:30, 5, 6, 9, 12, 15, 18, 24 hours. PD: 0, 6, 12, 24 hours. ]
Pharmacokinetic evaluation will be based on data obtained from the average dosage of somatropin plasma. Thus, the time of collection facilities provide the pharmacokinetic parameters AUC0-24h, AUC0-inf, Cmax, Tmax and T1 / 2, which will be compared between the two formulations.
The quantification of serum somatropin kit will be performed by ELISA validated using human serum as a biological matrix.
The evaluation of the pharmacodynamics will be performed by quantifying serum levels of IGF-1 presented by the concentration-time profile, AUC 0-24h and AUC0-inf.
- After administration of the drug will be evaluated for safety and tolerability of the drug through the presence of hematoma, pain, itching and local redness, as well as the incidence of adverse events directly related to somatropin. [ Time Frame: 15 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 32 Years (Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Research subjects who agree with all study procedures, sign and date, of their own free will, the IC;
- Research subjects were male, aged between 18 and 32 years;
- Research subjects with body mass index greater than or equal to 20 and less than or equal to 25;
- Considered healthy subjects, both clinical and laboratory.
Exclusion Criteria:
- Have donated or lost 450 mL or more blood in the 6 months preceding the study;
- Having participated in any experimental study or have taken any experimental drug in the 12 months preceding the start of the study;
- Having made use of regular medication less than two weeks to interfere with the pharmacokinetics / pharmacodynamics of the drug under study, such as glucocorticoids, anabolic steroids, androgens, estrogens and thyroid hormones;
- Present history of alcohol abuse, drug or drugs;
- Have a history of liver disease, renal, pulmonary, gastrointestinal, hematologic, or psychiatric;
- Have made previous use of somatropin;
- Make use of energy supplements and / or be frequent consumers of soy products (eg replacement of animal milk for soy milk).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01494779
Contact: Alexandre Frederico, physian | 55 19 3871-6399 | alexandre@lalclinica.com.br |
Brazil | |
LAL Clínica Pesquisa e Desenvolvimento Ltda | Not yet recruiting |
Valinhos, São Paulo, Brazil | |
Contact: Alexandre Frederico, phsycian 55 19 3871-6399 alexandre@lalclinica.com.br | |
Principal Investigator: Alexandre Frederico, phsycian |
Responsible Party: | Azidus Brasil |
ClinicalTrials.gov Identifier: | NCT01494779 History of Changes |
Other Study ID Numbers: |
SOMBLA0911 Version 1 |
First Posted: | December 19, 2011 Key Record Dates |
Last Update Posted: | September 25, 2012 |
Last Verified: | September 2012 |
Keywords provided by Azidus Brasil:
children |